Reuters logo
U.S. judge invalidates Mallinckrodt patents on respiratory treatment
September 5, 2017 / 3:17 PM / 20 days ago

U.S. judge invalidates Mallinckrodt patents on respiratory treatment

Sept 5 (Reuters) - A federal court in Delaware on Tuesday invalidated patents held by Mallinckrodt Pharmaceuticals on its Inomax respiratory treatment system.

The ruling came in a lawsuit brought by Mallinckrodt against specialty chemical company Praxair Inc, which sought to market a generic version of Inomax. The judge found Praxair did not infringe Mallinckrodt’s patents.

Reporting by Jan Wolfe; Editing by Jeffrey Benkoe

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below